### ü´Å Pulm/CC: Management of a Pure Ground-Glass Lung Nodule

#### ‚úÖ True Statements
1. The **recommended follow-up** for a pure ground-glass lung nodule larger than 6 mm is CT at 6‚Äì12 months, then repeat CT every 2 years for a total of 5 years.  
2. **Ground-glass nodules** can be very slow growing but often represent **premalignant disease**.  
3. **Development of a solid component** within a pure ground-glass nodule or enlargement of an existing solid component suggests **cancer** and requires more frequent follow-up or intervention.  
4. **PET/CT** is not useful for evaluating pure ground-glass nodules because of their **low metabolic activity**, and nodules 8 mm or smaller are not reliably characterized by PET/CT.  
5. **Repeat CT at 1 year** after a prior stable 12-month scan is not recommended because such a short interval is unlikely to show meaningful change.  
6. **No further testing** is inappropriate for pure ground-glass nodules because they require **5 years of surveillance** due to premalignant potential.  
7. **Key Point:** The recommended follow-up schedule for a pure ground-glass nodule larger than 6 mm is CT at 6‚Äì12 months and then every 2 years until 5 years.  

#### üí¨ Extra(s)
1. Ground-glass nodules have **doubling times of 400‚Äì800 days**, which explains the extended follow-up schedule.  
4. PET/CT is widely used for staging thoracic tumors and metastatic disease, but not for characterizing small ground-glass nodules.  

#### üìö Reference
Mazzone PJ, Lam L. Evaluating the patient with a pulmonary nodule: a review. JAMA. 2022;327(3):264-73. PMID: 35040882 doi:10.1001/jama.2021.24287  

#### üè∑Ô∏è Tags
#Pulm/CC #PulmonaryNodule #GroundGlass #CTFollowUp #FleischnerSociety #AmbulatoryCare  

#### üÜî Question ID
PMMCQ24032  

#### üïí Last Updated
February 2025  

---

#### üìñ Related Text
MKSAP: Pulmonary Medicine, Lung Tumors, Pulmonary Nodule Evaluation  

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. A **pulmonary nodule** is a small opacity less than 3 cm in diameter, surrounded by normal lung, and usually asymptomatic.  
2. A pulmonary opacity larger than 3 cm is a **lung mass** and presumed malignant until proved otherwise.  
3. Management of pulmonary nodules is guided by **size and imaging characteristics**, with follow-up based on the largest lesion when multiple are present.  
4. A well-demarcated, fully or centrally **calcified nodule** usually represents a benign infectious granuloma.  
5. Solid nodules larger than 8 mm require **malignancy risk estimation** before management.  
6. The **Brock model** estimates malignancy risk in pulmonary nodules and has high negative predictive value.  
7. Solid nodules with **moderate probability** of malignancy should be further characterized with PET/CT.  
8. Solid nodules with **high probability** of malignancy require PET/CT for staging and then surgical resection or systemic therapy.  
9. Solid nodules 8 mm or smaller are difficult to biopsy and not reliably characterized by PET; they are usually followed with serial CT.  
10. **Subsolid nodules** cannot be reliably characterized by PET, and nonsurgical biopsies have limited sensitivity.  
11. Development or enlargement of a **solid component** in a ground-glass nodule suggests malignancy.  

#### üí¨ Extra(s)
1. Pulmonary nodules are increasingly detected because of widespread CT imaging for other reasons.  
3. Shared decision-making is important in pulmonary nodule management.  
5. Estimating malignancy probability helps decide between surveillance, PET/CT, or invasive evaluation.  
9. Follow-up intervals for small nodules follow **Fleischner Society guidelines**.  
11. Subsolid nodules often represent **premalignant disease such as adenocarcinoma in situ**, which can grow slowly with doubling times of 400‚Äì800 days.  

#### üè∑Ô∏è Related Text Tags
#Pulm/CC #PulmonaryNodule #Evaluation #RiskStratification #PETCT #CTFollowUp #BrockModel  

---

#### üñºÔ∏è Supplemental Figure(s)
<figure><img src="/mnt/data/Radiographic Evolution of Part-Solid Pulmonary Nodule.jpg" alt="Radiographic Evolution of Part-Solid Pulmonary Nodule"><figcaption>Figure: Radiographic Evolution of Part-Solid Pulmonary Nodule.</figcaption></figure>

#### üîä Supplemental Video(s)
<!-- None -->

#### üóæ Supplemental HTML Table(s)
<table>
  <caption><strong>Fleischner Society Recommendations for Single Pulmonary Nodule Follow-Up</strong></caption>
  <thead>
    <tr><th>Risk Factors for Lung Cancer?</th><th>Size</th><th>Recommended Follow-Up</th></tr>
  </thead>
  <tbody>
    <tr><td>No (low-risk patient)</td><td>&lt;6 mm</td><td>No follow-up</td></tr>
    <tr><td></td><td>6 to 8 mm</td><td>CT at 6 to 12 mo, then consider CT at 18 to 24 mo</td></tr>
    <tr><td></td><td>&gt;8 mm</td><td>Consider CT at 3 mo, PET/CT, or tissue sampling</td></tr>
    <tr><td>Yes (high-risk patient)</td><td>&lt;6 mm</td><td>Optional CT at 12 mo</td></tr>
    <tr><td></td><td>6 to 8 mm</td><td>CT at 6 to 12 mo then CT at 18 to 24 mo</td></tr>
    <tr><td></td><td>&gt;8 mm</td><td>Consider CT at 3 mo, PET/CT, or tissue sampling</td></tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: Fleischner Society Recommendations for Single Pulmonary Nodule Follow-Up)
1. Low-risk patients with nodules <6 mm require no follow-up.  
2. Low-risk patients with nodules 6‚Äì8 mm should have CT at 6‚Äì12 months, then consider CT at 18‚Äì24 months.  
3. Low-risk patients with nodules >8 mm should have CT at 3 months, PET/CT, or tissue sampling.  
4. High-risk patients with nodules <6 mm may have optional CT at 12 months.  
5. High-risk patients with nodules 6‚Äì8 mm should have CT at 6‚Äì12 months and again at 18‚Äì24 months.  
6. High-risk patients with nodules >8 mm should have CT at 3 months, PET/CT, or tissue sampling.  

#### üí¨ Optional Extra(s)
2. More frequent follow-up reflects the higher malignancy risk in larger nodules.  
4. Optional CT follow-up for <6 mm nodules balances risk with radiation exposure.  

---

<table>
  <caption><strong>Fleischner Society Recommendations for Solitary Subsolid Lung Nodule Follow-Up</strong></caption>
  <thead>
    <tr><th>Imaging Findings</th><th>Size</th><th>Recommended Follow-Up</th></tr>
  </thead>
  <tbody>
    <tr><td>Pure ground glass</td><td>&lt;6 mm</td><td>No follow-up</td></tr>
    <tr><td></td><td>‚â•6 mm</td><td>CT at 6 to 12 mo to confirm persistence, then CT every 2 y until 5 y</td></tr>
    <tr><td>Part-solid nodule</td><td>&lt;6 mm</td><td>No follow-up</td></tr>
    <tr><td></td><td>‚â•6 mm</td><td>CT at 3 to 6 mo to confirm persistence; if unchanged and solid component remains &lt;6 mm, annual CT for 5 y</td></tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: Fleischner Society Recommendations for Solitary Subsolid Lung Nodule Follow-Up)
1. Pure ground-glass nodules <6 mm require no follow-up.  
2. Pure ground-glass nodules ‚â•6 mm should have CT at 6‚Äì12 months, then every 2 years until 5 years.  
3. Part-solid nodules <6 mm require no follow-up.  
4. Part-solid nodules ‚â•6 mm should have CT at 3‚Äì6 months; if unchanged and the solid component remains <6 mm, annual CT for 5 years is recommended.  

#### üí¨ Optional Extra(s)
2. Persistence of pure ground-glass nodules ‚â•6 mm suggests premalignant potential.  
4. Long-term follow-up of part-solid nodules is needed because of their slow malignant potential.  
